X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Viracta's lead program, VRx-3996 evaluates the all-oral combination of nanatinostat, its proprietary investigational drug, and valganciclovir in a Phase 2 clinical trial for the treatment of EBV-positive relapsed/refractory (R/R) lymphoma.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: VRx-3996
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
Nana-val (nanatinostat in combination with valganciclovir), a first-in-class, all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers. It is being evaluated for the treatment of relapsed or refractory EBV+ peripheral T-cell lymphoma.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
RZ-001 engenders effective anti-HCC activity by suppressing hTERT expression selectively in cancer cells, which over-express hTERT. It is being evaluated in Phase 1/2 clinical trials in combination With valganciclovir for the treatment of hepatocellular carcinoma.
Lead Product(s): RZ-001,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: RZ-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2024
Details:
Nana-val (nanatinostat in combination with valganciclovir), a first-in-class, all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers. It is being evaluated for the treatment of EBV-related nasopharyngeal carcinoma.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
Nana-val (nanatinostat + valganciclovir) is a combination medicine. Nanatinostat is an orally available histone deacetylase (HDAC) inhibitor. It is being evaluated in phase 1/2 clinical trials for the treatment of Epstein-Barr Virus-positive solid tumors.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
RZ-001, the RNA replacement enzyme-based cancer gene therapy for the treatment of GBM, targets and cleaves hTERT mRNA and replaces the mRNA with the therapeutic gene RNA.
Lead Product(s): RZ-001,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: RZ-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
Nana-val (nanatinostat) is an oral histone deacetylase inhibitor, selective for specific Class I HDACs isoform. It is currently being investigated in combination with valganciclovir for R/R EBV+ PTCL.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-Val
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
Nana-val (nanatinostat and valganciclovir) is an orally available histone deacetylase inhibitor. It is selective for specific isoforms of Class I HDACs, which are key to inducing viral genes that are epigenetically silenced in EBV-associated malignancies.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
Rznomics will leverage Charles River’s viral vector CDMO experience to initiate clinical development of its RNA-based anticancer gene therapy in liver cancer patients. RZ-001 is the first ribozyme-based RNA reprogramming approach approved by the US FDA.
Lead Product(s): RZ-001,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: RZ-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Charles River
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 18, 2023
Details:
Nana-val (nanatinostat) is an oral histone deacetylase inhibitor, selective for specific Class I HDACs isoforms, which induces viral genes that are epigenetically silenced in EBV associated malignancies. It is currently being investigated in combination with valganciclovir.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2023
Details:
VRx-3996 (nanatinostat), an orally available HDAC inhibitor, is selective for specific isoforms of Class I HDACs, which are key to inducing viral genes that are epigenetically silenced in Epstein-Barr virus (EBV)-associated malignancies.
Lead Product(s): Nanatinostat,Pembrolizumab,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: VRx-3996
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
RZ-001 engenders effective anti-HCC activity by suppressing hTERT expression selectively in cancer cells, which over-express hTERT, and simultaneously inducing a cytotoxic effect by trans ligating an HSVtk-encoding sequence into the reprogrammed hTERT mRNA.
Lead Product(s): RZ-001,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: RZ-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
Nana-val (nanatinostat) is selective for specific isoforms of Class I HDACs, which is key to inducing viral genes that are epigenetically silenced in Epstein-Barr virus (EBV)-associated malignancies.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Nana-val (Nanatinostat and Valganciclovir), is an orally available HDAC inhibitor, is selective for specific isoforms of Class I HDACs, which is key to inducing viral genes that are epigenetically silenced in EBV-associated malignancies.
Lead Product(s): Nanatinostat,Pembrolizumab,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: VRx-3996
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
Nana-val (Nanatinostat and Valganciclovir), is an orally available histone deacetylase (HDAC) inhibitor, which is key to inducing viral genes that are epigenetically silenced in EBV-associated malignancies.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
Viracta's lead program (VRx-3996) evaluates the all-oral combination of nanatinostat, its proprietary investigational drug, and valganciclovir in a Phase 2 clinical trial for the treatment of EBV-positive relapsed/refractory (R/R) lymphoma.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: VRx-3996
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sunesis Pharmaceuticals
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Merger February 24, 2021
Details:
Proceeds will support Viracta's lead program that evaluates all-oral combination of nanatinostat and valganciclovir in a Phase 2 clinical trial for the treatment of EBV-positive relapsed/refractory (R/R) lymphoma.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BVF Partners
Deal Size: $65.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 24, 2021
Details:
The merger will focus on the advancement and expansion of Viracta’s clinical stage, precision oncology pipeline including Viracta’s lead program of all-oral combination of nanatinostat and valganciclovir to teat Epstein-Barr virus-positive relapsed/refractory lymphomas.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: VRx-3996
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sunesis Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 30, 2020
Details:
The allowed application, titled "Methods and Compositions for Treating Viral or Virally-induced Conditions," protects the use of Viracta's all-oral combination product candidate of nanatinostat.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: VRx-3996
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
Phase 2 all-oral combination product of nanatinostat and valganciclovir has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: VRx-3996
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Details:
Viracta will provide an update on the clinical development of the company's lead program, nanatinostat in combination with the antiviral valganciclovir as an oral combination therapy in a Phase 2 clinical trial for the treatment of EBV-associated lymphoma.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020
Details:
Viracta has developed a novel approach to selectively target malignant cells associated with EBV that is applicable across many cancer types,may also have utility in other virus-associated diseases.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
